# Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

> **NCT04158440** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 501 (actual)

## Conditions studied

- Stage II-III Non-small Cell Lung Cancer

## Interventions

- **DRUG:** 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
- **DRUG:** 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )

## Key facts

- **NCT ID:** NCT04158440
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-07
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158440, "Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04158440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*